Day: March 30, 2023

NORCROSS, Ga., March 30, 2023 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2022. These results are included in the Company’s Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said: “As previously reported, we completed recruitment in late December 2022 and randomization by the end of February 2023 in our adaptively designed Phase 2b/3 NAVIGATE trial for the prevention of esophageal varices in patients with NASH cirrhosis with a total of 357 patients. We randomized more patients than we had...

SEATTLE, Wash. and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced changes to the Company’s Board of Directors to continue to support the future direction of the Company. As provided in the previously reported Cooperation Agreement, as amended, between the Company and certain of its shareholders, Mr. Stuart Duty, Mr. Thomas King, and Mr. Tom Sellig have been appointed to the Board of Directors and will be nominated for election at the Company’s Annual Meeting of Stockholders to be held in June 2023. Additionally, each of Mr. Donald Joseph, Dr. Martin Mattingly, and Mr. Jay Moyes will not be nominated...

– Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Dosed the first patient in the investigator sponsored Phase 1 clinical trial of VCN-01 for patients with brain tumors – – Presented positive safety and pharmacokinetic data from the ongoing Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients at 2023 Tandem Meetings Transplantation & Cellular Therapy Meetings; Dosed the first patient in Cohort 2 – – As of December 31, 2022, Theriva Biologics reports $41.8 million in cash, which is expected to provide runway into the third quarter of 2024 – – Conference call and webcast to be held on Thursday, March 30th at 8:30 a.m. ET – ROCKVILLE, Md., March 30, 2023 (GLOBE...

QUEBEC CITY, March 30, 2023 (GLOBE NEWSWIRE) — (TSX: HEO) – H2O Innovation Inc. (“H2O Innovation” or the “Corporation”) is proud to announce that its Operation and Maintenance (O&M) business line has received two recognition awards, which speak to the team’s continued dedicated service and great performance. For the third year in a row, the Corporation’s O&M contract with the City of Canton, GA, was honored with the Gold Award by the Georgia Association of Water Professionals (GAWP). This award recognizes exceptional performance in the delivery of safe drinking water and the protection of Georgia’s water resources, as this type of leadership is essential to a prosperous future for all Georgians. “Congratulations to H2O Innovation and all the staff at the water plant for continued outstanding service. This is well deserved,” stated...

InnovAge Diversifies Board of Directors with New Independent Director InnovAge announced the appointment of Patty Fontneau to its Board of Directors, effective immediately.DENVER, March 30, 2023 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced the appointment of Patty Fontneau to its Board of Directors, effective immediately. Fontneau joins InnovAge’s Board as Pavithra Mahesh of Apax Partners and Caroline Dechert of Welsh, Carson, Anderson & Stowe simultaneously step down from their positions with the Board. These changes maintain the participation of the investment firms while adding additional independent and community representation...

Company has completed Phase 3 manufacturing of PDS0101 for randomized, controlled, registrational trial in recurrent/metastatic HPV16-positive head and neck cancer FLORHAM PARK, N.J., March 30, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced that it has completed key tech transfer, scale up and manufacturing activities required to initiate a global, multicenter Phase 3 registrational trial investigating the combination of PDS0101 and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in the fourth quarter of 2023. The Phase 3 trial, named VERSATILE-003, will investigate the combination compared to KEYTRUDA® monotherapy for the treatment of unresectable, recurrent/metastatic...

Effort to Increases News Flow to Investors via Social Media ARLINGTON, Va., March 30, 2023 (GLOBE NEWSWIRE) — Edge Total Intelligence Inc. (“edgeTI” or the “Company”) (TSXV: CTRL, OTCQB: UNFYF, FSE: Q5i), is pleased to announce it has engaged Toronto-based marketing firm Outside the Box Capital, the acquired and rebranded firm of former North Equities Corp. to provide marketing services via social media channels to investors. Outside the Box Capital specializes in social media platforms and will be able to facilitate greater awareness and widespread dissemination of the Company’s news into these channels. “We strive to support companies with an under told story that are doing something extremely innovative,” said Jason Coles, CEO of Outside the Box Capital. “We are thrilled to be working alongside edgeTI during this exciting...